Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone For Advanced Prostate Cancer: Updated Survival In The TAX 327 Study
UroToday.com- The TAX 327 study was reported in 2004 and evaluated patients with hormone-refractory prostate cancer (HRPC) in three treatment arms; docetaxel 75mg/m2 every 3 weeks (D3P), docetaxel 30mg/ m2 weekly (D1P), or mitoxantrone 12 m2 every 3 weeks (MP), each with prednisone 5mg twice daily. It demonstrated significant survival benefit to D3P compared to MP but no significant difference to D1P. D3P also had better palliation. At that report, 557 of 1,006 participants had died.
More: continued here